Gene Devine
Super Moderator
Came across this study:
Central serous chorioretinopathy in patients receiving exogenous testosterone therapy.
http://www.ncbi.nlm.nih.gov/pubmed/24946102
Purpose: To report an association between central serous chorioretinopathy (CSCR) and
exogenous testosterone therapy.
Methods: This is a retrospective case series from two institutions. Patients who
presented with fluorescein angiography and optical coherence tomography findings
consistent with CSCR were included. All patients were concurrently being treated with
exogenous testosterone therapy and lacked other known risk factors for CSCR.
Results: Nine patients presented with CSCR after beginning exogenous testosterone
therapy. Two patients stopped therapy with resolution of symptoms and subretinal fluid.
Conclusion: Exogenous testosterone may be an independent risk factor for the
development of CSCR.
Nine patients presented with CSCR and two had to stop...how many patients were tested? If this was a serious enough side effect it would be on the drug package insert...Testosterone has been around for many decades and it appears not to be a concern to the FDA or it would be on the insert as a side effect like all drugs have side effects.